Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18539727 | 0.89 | ALDH1A1 (0.48) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL213761 | 0.78 | MAPT (0.54) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL213762 | 0.78 | MAPT (0.54) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL5820805 | 0.70 | ALDH1A1 (0.64) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL18539720 | 0.70 | MAPT (0.51) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL18539669 | 0.70 | CNR2 (0.48) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL13078705 | 0.67 | ALDH1A1 (0.40) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL13044364 | 0.67 | GRIN2D (0.51) | ALDH1A1KMT2AMAPTLMNAMEN1 | |
| SCHEMBL13078614 | 0.66 | GCGR (0.44) | ALDH1A1KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL13490857 | 0.65 | POLB (0.66) | ALDH1A1KMT2AMAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3438134-B1 | POLYMERIZABLE COMPOSITION, CURED OBJECT, OPTICAL FILM FOR DISPLAY, AND PROCESS FOR PRODUCING CURED OBJECT | ADEKA CORP (JP) | 2021-05-05 | — | — | EP | disclosed |
| EP-3438134-A1 | POLYMERIZABLE COMPOSITION, CURED OBJECT, OPTICAL FILM FOR DISPLAY, AND PROCESS FOR PRODUCING CURED OBJECT | Adeka Corporation (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-10189847-B2 | Oxime ester compound and photopolymerization initiator containing said compound | ADEKA CORPORATION (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20170166575-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING SAID COMPOUND | ADEKA CORPORATION (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166575-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING SAID COMPOUND | ADEKA CORPORATION (JP) | 2017-06-15 | — | — | US | disclosed |
| WO-2017030005-A1 | COMPOSITION | 株式会社ADEKA | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166575-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING SAID COMPOUND | RB1, PRMT9, KDM2B | ALDH1A1 1211/4885KMT2A 224/4885MAPT 3454/4885 |
| US-10189847-B2 | Oxime ester compound and photopolymerization initiator containing said compound | PPOX, CCNO, MRTO4 | ALDH1A1 1193/4885KMT2A 185/4885MAPT 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.